Gsk (GSK) EBIT Margin (2009 - 2026)

Gsk (GSK) has 18 years of EBIT Margin data on file, last reported at 17.3% in Q3 2026.

• For the quarter ending Q3 2026, EBIT Margin changed N/A year-over-year to 17.3%; the trailing twelve-month figure through Sep 2026 stood at 15.13% (changed N/A YoY), and the FY2025 full-year result was 24.28%, up 1147.0% from the prior year.
• EBIT Margin was 17.3% for Q3 2026 at Gsk, up from 5.72% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 31.89% in Q1 2022 to a low of 2.36% in Q3 2024.
• A 5-year average of 21.87% and a median of 23.9% in 2022 frame the typical range for EBIT Margin.
• Across the five-year window, EBIT Margin plunged 2156 bps in 2024 and jumped 2798 bps in 2025, its largest moves.
• Gsk's EBIT Margin stood at 23.9% in 2022, then rose by 25 bps to 29.89% in 2023, then tumbled by 31 bps to 20.57% in 2024, then plunged by 37 bps to 12.98% in 2025, then jumped by 33 bps to 17.3% in 2026.
• Per Business Quant data, the three most recent EBIT Margin figures were 17.3% in Q3 2026, 5.72% in Q2 2026, and 30.06% in Q1 2026.